摘要
目的观察明睛颗粒治疗湿性老年性黄斑变性临床疗效。方法本研究为临床配对研究,将120例(120眼)患者根据年龄、就诊时间、眼底特征进行1∶1配对研究,分为两组,每组60例(60眼),明睛颗粒组用明睛颗粒中药治疗,对照组用光动力疗法进行治疗,观察指标包括最佳矫正视力、眼底出血渗出面积、视网膜厚度、临床花费等。结果治疗3个月,两组患者视力及眼底疗效相当,差异均无统计学意义(视力疗效:Z=0.960,P=0.337;眼底疗效:Z=0.739,P=0.460);各组治疗前后眼部症状如眼底出血、渗出面积、矫正视力、视网膜厚度等情况比较:明睛颗粒组治疗后眼底出血渗出面积较治疗前减小,差异有统计学意义(t=2.055,P=0.047),视力、视网膜厚度比较差异均无统计学意义(视力:t=-0.712,P=0.479;视网膜厚度:t=-0.292,P=0.780);对照组治疗前后出血渗出面积、视力、视网膜厚度等改善不明显,差异均无统计学意义(均为P>0.05);对脉络膜新生血管(CNV)的抑制方面,明睛颗粒治疗3个月,CNV活动性下降,但差异无统计学意义(Z=1.907,P=0.057),治疗6个月,CNV活动性明显减少,差异有统计学意义(Z=-4.846,P=0.000);两组医疗费用比较,明睛颗粒组为(3160.17±1309.34)元,对照组为(32 349.33±7897.94)元,差异有统计学意义(t=11.519,P=0.000)。随访3个月,两组均没有明显并发症发生。结论明睛颗粒和光动力疗法相比,均能够稳定并提高湿性老年性黄斑变性患者的视力,促进眼底出血渗出吸收,抑制新生血管的活动性,但临床医疗费用较低。因此,明睛颗粒也是治疗湿性老年性黄斑变性的一种不错的选择。
Objective To investigate the clinical efficacy of Chinese medicine MingJing KeLi for wet age-related macular degeneration. Methods Matched pair clini- cal study. A total of 120 patients （ 120 eyes） were paired and divided into two groups based on their age, course of disease and fundus features, 60 cases in each group. The experimental group was treated by MingJing KeLi. The controlled group was treated by photodynamic therapy （PDT）. The observation indexes included best corrected visual acuity （BCVA）, area of retinal hemorrhage and exudates, retinal thickness and cost of treatment. Results After treatment of 3 months, there was no statistical difference in the efficacy of visual acuity and fundus （ Z = 0. 960,0. 739 ;P = 0. 337 ,0. 450） . There were statistical differences in the areas of bleeding and exudates in the fundus between be- fore and after treatment in MingJing KeLi group （ t = 2.055 ,P = 0.047 ） ,but no statistical difference in BCVA and retinal thickness （ t = - 0.712, - 0.292 ;P = 0. 479,0. 780）. There was no statistical difference in the areas of bleeding and exudates in the fundus, BCVA, retinal thickness between before and after treatment in PDT group （ all P 〉 0.05 ）. In in- hibiting the activity of CNV with MingJing KeLi, there was no significant difference at the time point of 3 months（ Z = 1. 907 ,P = 0.057 ）, however, when observed at 6 months after treatment, the activity of CNV decreased obviously （ Z = - 4. 846, P = 0. 000 ）. The average cost of MingJing KeLi group and PDT group were （3150.17 _＋ 1309.34）yuan and （32 549.33 ± 7897.94）yuan, respectively ,there was statistical difference（ t = 11. 519 ,P = 0.000）. After follow up of 3 months, there was no obvious complication in two groups. Conclusion Compared with PDT,MingJing KeLi can stablize and improve the visual acuity, promote absorption of retinal hemorrhage and exudates, inhibit CNV activity and reduce the clinical costs in patients with wet age-related macular degeneration. So it is a good choice to treat wet age-related macular degeneration.
出处
《眼科新进展》
CAS
北大核心
2014年第2期155-157,共3页
Recent Advances in Ophthalmology
基金
首都医学科技发展基金(编号:2005-SF-Ⅱ-010)
十一五国家科技支撑项目(编号:2006BAI04A18)~~
关键词
老年性黄斑变性
明睛颗粒
光动力疗法
脉络膜新生血管
age-related macular degeneration
MingJing KeLi
photodynamic ther- apy
choroidal neovascularization
